| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/24/2010 | US20100158955 Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity |
| 06/24/2010 | US20100158931 Novel immunotherapy against several tumors including neuronal and brain tumors |
| 06/24/2010 | US20100158929 Novel formulations of tumour-associated peptides binding to human leukocyte antigen (hla) class i or class ii molecules for vaccine |
| 06/24/2010 | US20100158924 Expression of the cysteine protease legumain in vascular and inflammatory diseases |
| 06/24/2010 | US20100158923 Reducing polyglutamine-based aggregation |
| 06/24/2010 | US20100158921 Compositions and methods for inhibition of the jak pathway |
| 06/24/2010 | US20100158918 Polypeptides and polynucleotides encoding same |
| 06/24/2010 | US20100158914 Klotho beta |
| 06/24/2010 | US20100158912 Monitoring and inhibiting human immunodeficiency virus infection by modulating hmgb1 dependent triggering of hiv-1 replication and persistence |
| 06/24/2010 | US20100158911 Compositions and Methods of Treating Disease with FGFR Fusion Proteins |
| 06/24/2010 | US20100158907 Connective tissue growth factor fragments and methods and uses thereof |
| 06/24/2010 | US20100158906 Use of recombinant monoclonal antibody with specific binding activity for cell surface phosphorylated glycoprotein in diagnosis and treatment of immune, cell proliferative and inflammatory disorders |
| 06/24/2010 | US20100158905 Combination therapy of arthritis with tranilast |
| 06/24/2010 | US20100158899 Protein formulation |
| 06/24/2010 | US20100158895 Methods and compositions for reduction of side effects of therapeutic treatments |
| 06/24/2010 | US20100158891 Human Coagulation Factor VII Variants |
| 06/24/2010 | US20100158890 Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors |
| 06/24/2010 | US20100158889 Enhancing the effect of therapeutic proteins on the central nervous system |
| 06/24/2010 | US20100158888 Use of alkaline phosphatase to maintain healthy tissue mass in mammals |
| 06/24/2010 | US20100158887 Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity |
| 06/24/2010 | US20100158886 Triple acting antimicrobials that are refractory to resistance development |
| 06/24/2010 | US20100158885 Method and material for site activated complexing of biologic molecules |
| 06/24/2010 | US20100158884 Cascade |
| 06/24/2010 | US20100158883 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 06/24/2010 | US20100158866 Prediction of hcv treatment response |
| 06/24/2010 | US20100158865 Inhibitor of endogenous human interferon-gamma |
| 06/24/2010 | US20100158864 Antiviral product |
| 06/24/2010 | US20100158863 Triazoloanilinopyrimidine derivatives for use as antiviral agents |
| 06/24/2010 | US20100158862 Hepatitis C Virus Inhibitors |
| 06/24/2010 | US20100158861 Treating idiopathic thrombocytopenic purpura with compositions comprising extracts of astragalus membranaceus |
| 06/24/2010 | US20100158860 Heterocyclic antiviral compounds |
| 06/24/2010 | US20100158859 Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| 06/24/2010 | US20100158858 Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| 06/24/2010 | US20100158857 Compositions and methods for the inhibition of endothelial nitric oxide synthase activity |
| 06/24/2010 | US20100158856 Assays and methods using biomarkers |
| 06/24/2010 | US20100158849 Isocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant |
| 06/24/2010 | US20100158829 Method and Composition for Color Modulation |
| 06/24/2010 | US20100158824 Silicone polyether elastomer gels |
| 06/24/2010 | US20100158822 Peptides that bind to silica-coated particles |
| 06/24/2010 | US20100158814 Fibrin-Binding Peptides and Conjugates Thereof |
| 06/24/2010 | US20100158809 Truncated pap2 and methods of making and using same |
| 06/24/2010 | US20100158806 Compositions for Delivery of Therapeutics and Other Materials |
| 06/24/2010 | US20100158803 Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies |
| 06/24/2010 | US20100158800 Drug depot implant designs and methods of implantation |
| 06/24/2010 | US20100158799 Method and composition for bioactive agent release in vivo |
| 06/24/2010 | US20100158796 Amides of hyaluronic acid and the derivatives thereof and a process for their preparation |
| 06/24/2010 | DE102008063046A1 Medizinische Verwendung des ribosomalen Protein S19 (RPS19) Medical use of the ribosomal protein S19 (RPS19) |
| 06/24/2010 | CA2752506A1 Method for treating prostatitis utilizing modified pore-forming protein proaerolysin |
| 06/24/2010 | CA2747721A1 Tfpi inhibitors and methods of use |
| 06/24/2010 | CA2747682A1 Method to select animals with a high capacity of embryo production |
| 06/24/2010 | CA2747678A1 Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| 06/24/2010 | CA2747508A1 Bone grafts with reduced protease activity and methods of selection and use |
| 06/24/2010 | CA2747499A1 Amide based glucagon superfamily peptide prodrugs |
| 06/24/2010 | CA2747220A1 Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| 06/24/2010 | CA2747155A1 Glucagon analogues |
| 06/24/2010 | CA2747065A1 Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| 06/24/2010 | CA2745377A1 Anticancer compounds |
| 06/24/2010 | CA2743181A1 Methods related to modified glycans |
| 06/24/2010 | CA2706317A1 Doc1 compositions and methods for treating cancer |
| 06/23/2010 | EP2199799A1 Method to select animals with a high capacity of embryo production |
| 06/23/2010 | EP2199387A1 Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders |
| 06/23/2010 | EP2199305A1 Peptides against autoantibodies associated with CRPS and use of these peptides |
| 06/23/2010 | EP2199299A2 Antisense modulation of survivin expression |
| 06/23/2010 | EP2198890A1 Combinatorial libraries of monomer domains |
| 06/23/2010 | EP2198888A2 Sustained release of microcrystalline peptide suspensions |
| 06/23/2010 | EP2198887A1 Therapeutic agent for leukoderma and method for acceleration of pigmentation |
| 06/23/2010 | EP2198882A2 Nucleic acid mucosal immunization |
| 06/23/2010 | EP2198880A1 Compositions containing lipase, protease and amylase for treating pancreatic insufficiency |
| 06/23/2010 | EP2198879A1 CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell |
| 06/23/2010 | EP2198878A1 Polypeptide bombesin antagonists |
| 06/23/2010 | EP2198877A2 Orally administered peptides to ameliorate atherosclerosis |
| 06/23/2010 | EP2198876A1 A method for reducing the likelihood of implantation failure in a subject |
| 06/23/2010 | EP2198875A1 A method for reducing the likelihood of preterm labour in a subject in need thereof |
| 06/23/2010 | EP2198723A1 Inflammation inhibiting compounds |
| 06/23/2010 | EP2198304A2 Molecules and methods for treatment and detection of diabetes |
| 06/23/2010 | EP2198022A1 Designed armadillo repeat proteins |
| 06/23/2010 | EP2198021A1 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
| 06/23/2010 | EP2197909A2 Receptor-targeting reagents |
| 06/23/2010 | EP2197903A1 Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| 06/23/2010 | EP2197901A1 Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
| 06/23/2010 | EP2197900A2 Mutant double cyclized receptor peptides inhibiting 1-adrenoceptor antibodies |
| 06/23/2010 | EP2197899A2 Cyclic peptides comprising at least one aza- beta3-aminoacyl residue and uses thereof |
| 06/23/2010 | EP2197897A1 Amino acid pairing-based self assembling peptides and methods |
| 06/23/2010 | EP2197479A1 Inositol pyrophosphates determine exocytotic capacity |
| 06/23/2010 | EP2197478A1 Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| 06/23/2010 | EP2197477A2 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s) |
| 06/23/2010 | EP2197475A2 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission |
| 06/23/2010 | EP2197474A1 Use of soluble ceacam8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 06/23/2010 | EP2197473A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 06/23/2010 | EP2197471A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 06/23/2010 | EP2197470A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 06/23/2010 | EP2197468A1 Pegylation by the dock and lock (dnl) technique |
| 06/23/2010 | EP2197466A2 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 06/23/2010 | EP2197465A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 06/23/2010 | EP2197463A2 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections |
| 06/23/2010 | EP2197462A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 06/23/2010 | EP2197461A1 Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
| 06/23/2010 | EP2197436A1 Preparation and a component intended to be added to a tobacco product |
| 06/23/2010 | EP2197418A2 Biodegradable implants with controlled bulk density |
| 06/23/2010 | EP1670514B1 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |